Specific treatment of Chagas disease: Current status and new developments

Current Opinion in Infectious Diseases

Volumn 14, Issue 6, 2001, Pages 733-741

  Urbina, Julio A ^a  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; CRUZIPAIN; CYSTEINE PROTEINASE INHIBITOR; NITROIMIDAZOLE DERIVATIVE; STEROL;

ANTIFUNGAL ACTIVITY; CELL VIABILITY; CHAGAS DISEASE; CHRONIC DISEASE; DRUG EFFECT; HUMAN; KINETOPLAST; POLYMERASE CHAIN REACTION; PROTOZOAL INFECTION; REVIEW; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS;

EID: 0035211508     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200112000-00012     Document Type: Review

References (62)

1. The Mechanism of Trypanosoma cruzi invasion of mammalian cells
2. Chagas' disease (American trypanosomiasis): A tropical disease now emerging in the United States
3. Epidemiology of Chagas disease
4. Chemotherapy of human leishmaniasis and trypanosomiasis
5. Chemotherapy of Chagas' disease: The how and the why
6. Parasitological cure of Chagas disease: Is it possible?, Is it relevant?
7. Immunology
8. Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease
9. Autoimmunity in Chagas disease cardiopathy: Biological relevance of a cardiac myosin-specific epitope crossreactive to an immunodominant Trypanosoma cruzi antigen
10. Autoimmunity in Chagas disease cardiomyopathy: Fulfilling the criteria at last?
11. Chagas disease ethiology: Autoimmunity or parasite persistence?
12. Treatment of chronic Chagas' disease with benznidazole: Clinical and serologic evolution of patients with long-term follow-up
13. Randomised trial of efficacy of benznidazole in treatment of early Trypanossoma cruzi infection
14. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas disease
15. Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines in Argentina
16. Parasite persistence in the aetiology of Chagas disease
17. Therapy of Chagas disease
18. Specific chemotherapy
19. Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14-30 years ago
20. Persistent infections in chronic Chagas disease patients treated with anti-Trypanosoma cruzi nitroderivatives
21. Criteria of Chagas disease cure
22. Evaluation of the effects of specific treatment against Trypanosoma cruzi on the evolution of indeterminate chronic Chagas disease
23. Chagas disease and immunosuppression
24. Reactivation of Chagas' disease in a human immunodeficiency virus-infected patient leading to severe heart disease with a late positive direct microscopic examination of the blood
25. Protective effect of benznidazole against parasite reactivation in patients chronically infected with Trypanosoma cruzi and treated with corticoids for associated disease
26. Benznidazole in the primary chemoprophylaxis of the reactivation of Chagas disease in chronic patients using corticosteroids at immunosuppressive doses: Is there sufficient evidence for recommending its use?
27. Sterol biosynthesis inhibitors for Chagas' disease
28. Cure of short- and long-term experimental Chagas disease using D0870
29. Activity of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts
30. In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi. Effects of immunosuppression
31. Cure of experimental Chagas' disease by the bis-triazole D0870 incorporated into 'stealth' polyethyleneglycol-polylactide nanospheres
32. Ravuconazole single ascending oral dose study in healthy subjects
33. Ravuconazole: Multiple ascending oral dose study in healthy subjects
34. In vitro and in vivo activities of the triazole derivative BMS-207147 (Ravuconazole) against Trypanosoma cruzi, the causative agent of Chagas disease
35. In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformans
36. Activities of TAK-187 against drug-resistant strains of the protozoan parasite Trypanosoma cruzi
37. New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones
38. In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi
39. The inhibition of cell signaling pathways by antitumor ether lipids
40. Mechanism of action of phospholipid analogs as anticancer compounds
41. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei
42. Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice
43. Effect of alkyllysophospholipids on the proliferation and differentiation of Trypanosoma cruzi
44. Activities of hexadecylphosphocholine (miltefosine), Ambisome and sodium stibogluconate (pentostam) against Leishmania donovani in immunodeficient scid mice
45. Trial of oral miltefosine for visceral leishmaniasis
46. Oral treatment of visceral leishmaniasis with miltefosine
47. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis
48. Mechanism of action of antiproliferative alkyl-lysophospholipids against the protozoan parasite Trypanosoma cruzi. Potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole
49. The cysteine proteinase of Trypanosoma cruzi as a model for antiparasite drug design
50. Cysteine protease inhibitors cure experimental Trypanosma cruzi infection
51. Trypanocidal effect of cysteine protease inhibitors in vitro and in vivo in experimental Chagas disease
52. Aryl ureas represent a new class of antitrypanosomal agents
53. Specific treatment of Chagas disease
54. Chemotherapy of Chagas disease
55. Trypanosoma cruzi: Effect of allopurinol in the treatment of mice with experimental acute Chagas' disease
56. Effects of allopurinol on different strains of Trypanosoma cruzi
57. Chagas Disease
58. Allopurinol in chronic Chagas disease
59. Efficient incorporation of inhibitors targeting the closed active site conformation of HPRT from Trypanosoma cruzi
60. Effects of fluorinated inositols on the phosphoinositides metabolism of Trypanosoma cruzi
61. Inositol metabolism in Trypanosoma cruzi: Potential target for chemotherapy against Chagas disease